Protein / target
Prostaglandin F2-alpha receptor
Protein at a glance
Biological role
Prostaglandin F receptor
Strongest disease association
Glaucoma, Open-Angle
Therapeutic position
Established drug target
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function overview
Receptor for prostaglandin F2-alpha (PGF2-alpha).
View complete UniProt function annotationHide complete annotation
Receptor for prostaglandin F2-alpha (PGF2-alpha). The activity of this receptor is mediated by G proteins which activate a phosphatidylinositol-calcium second messenger system. Initiates luteolysis in the corpus luteum (By similarity). Isoforms 2 to 7 do not bind PGF2-alpha but are proposed to modulate signaling by participating in variant receptor complexes; heterodimers between isoform 1 and isoform 5 are proposed to be a receptor for prostamides including the synthetic analog bimatoprost
Subcellular location
Domains and Gene Ontology detail (13)Hide
Gene Ontology
- Ccytoplasm
- Cextracellular region
- Cplasma membrane
- Fprostaglandin F receptor activity
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
- Pcellular response to prostaglandin D stimulus
- PG protein-coupled receptor signaling pathway
- Pinflammatory response
- Pparturition
- Ppositive regulation of cell population proliferation
- Ppositive regulation of cytosolic calcium ion concentration
- Ppositive regulation of gene expression
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
Cell proliferation & survival
- ·positive regulation of cell population proliferation
G protein-coupled signalling
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
- ·G protein-coupled receptor signaling pathway
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Approved medicines with mapped indications
Approved therapies targeting this protein, grouped by what they are approved to treat — the disease-first view of the medicines below. Relationships come from the canonical approved-indication graph (ChEMBL phase-4), the same source as the drug cards.
7 medicines meet Open Targets' target-level approved-medicine definition; the 3 shown here are those on this page with a canonical approved disease indication in the graph. Approved indications from ChEMBL (phase-4), via the canonical drug→disease graph.
Drugs targeting this protein
How approved and investigational drugs engage this protein — mechanism and action type, direct vs complex targeting, and how broadly each acts across other targets. A drug-first view (the section above groups the approved ones disease-first); direct binders with few recorded targets are listed first.
Prostanoid FP receptor agonist
Indicated for Glaucoma, Glaucoma, Open-Angle, Hypertension, Ocular Hypertension
Prostanoid FP receptor agonist
Indicated for Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
Prostanoid FP receptor agonist
Indicated for Glaucoma, Glaucoma, Open-Angle, Ocular Hypertension
ChEMBL mechanism, action type, target identity and approved indications. Open Targets clinical status.
Translational evidence
Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.
Strongest disease associations · via encoding gene PTGFR
Gene-level evidence surfaced through the gene PTGFRthat encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.
View evidence synthesis (5)Hide
The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.
Show all associationsHide all associations
Drug development
11 compounds recorded · 7 approved · 3 in clinical development · 1 earlier-stage
View all recorded compounds (10)Hide
Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.
Tractability
Small molecules — Strong
Antibodies — Emerging
Protein degraders — Emerging
View underlying tractability evidence (8)Hide
Raw Open Targets tractability assessment buckets, by modality.
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein. Ranked by active status, then clinical phase and recency, and spread across the targeting drugs.
View all trials (26)Hide
ClinicalTrials.gov via the drug-target graph.
What's happening now
Recent therapeutic activity around this target — regulatory actions, clinical trials and safety signals for 3 drugs that target this protein, plus publications where such a drug is a genuine subject. Every item is reached indirectly through the drug, not the protein itself; incidental mentions (a paper that merely measures a drug) and press items are excluded.
- Regulatory approval
Approval: Catiolanze (EMA)
- Safety communication
Drug Safety Update: Latanoprost (Xalatan): increased reporting of eye irritation since reformulation
- New publicationA randomised, controlled comparison of latanoprostene bunod and latanoprost 0.005% in the treatment of ocular hypertension and open angle glaucoma: the VOYAGER study.
- Regulatory approval
Approval: Izba (EMA)
- New publicationDiurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy.
- Regulatory approval
Approval: Lumigan (EMA)
- Regulatory approval
Approval: Travatan (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.
Related family literature
Papers about “Receptors, Prostaglandin” — a broader family this protein belongs to. Shown as context; not counted as papers specifically about this protein.
via Receptors, Prostaglandin
Europe PMC literature, reached through curated HGNC family membership. Membership is a taxonomic relationship — it does not imply this protein participates in every mechanism these papers discuss.